<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03268135</url>
  </required_header>
  <id_info>
    <org_study_id>RNA-HF-AS</org_study_id>
    <nct_id>NCT03268135</nct_id>
  </id_info>
  <brief_title>Heart Failure and Aortic Stenosis Transcriptome</brief_title>
  <acronym>RNA-HF-AS</acronym>
  <official_title>Study of the Transcriptomic Alterations in Heart Failure and Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Donato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale San Raffaele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Policlinico S. Donato</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to investigate the global transcriptome in order to determine the
      expression profile of messenger RNAs (mRNAs), as well as long noncoding- (lncRNAs) and micro
      noncoding-RNAs (miRNAs) in heart failure (HF) and in aortic stenosis (AS). The aim is to
      clarify their role in cardiac disease pathogenesis, as well as their potential as biomarkers.
      To this purpose, both tissue and blood specimens will be collected and patients will be
      compared to individuals not affected by cardiovascular diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will collect plasma and cardiac tissue specimens from consenting subjects.
      The investigators will evaluate the expression of mRNAs, miRNAs and lncRNAs in patients
      affected by both end-stage and not end-stage HF as well as in patients affected by aortic
      stenosis and undergoing valve replacement and requiring cardiac myectomy. The tissue
      dysregulated RNAs will be next measured in plasma samples in order to clarify their potential
      as biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac tissutal mRNAs signatures</measure>
    <time_frame>from Year 1 to Year 3</time_frame>
    <description>The mRNAs cardiac tissutal signatures of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac tissutal miRNAs signatures</measure>
    <time_frame>from Year 1 to Year 3</time_frame>
    <description>The miRNAs cardiac tissutal signatures of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac tissutal lncRNAs signatures</measure>
    <time_frame>from Year 1 to Year 3</time_frame>
    <description>The lncRNAs cardiac tissutal signatures of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non end-stage, end-stage heart failure, aortic stenosis mRNAs signatures in plasmas</measure>
    <time_frame>from Year 3 to Year 5</time_frame>
    <description>The mRNAs dysregulated in cardiac tissues will be measured in blood plasma samples of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non end-stage, end-stage heart failure, aortic stenosis miRNAs signatures in plasmas</measure>
    <time_frame>from Year 3 to Year 5</time_frame>
    <description>The miRNAs dysregulated in cardiac tissues will be measured in blood plasma samples of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non end-stage, end-stage heart failure, aortic stenosis lncRNAs signatures in plasmas</measure>
    <time_frame>from Year 3 to Year 5</time_frame>
    <description>The lncRNAs dysregulated in cardiac tissues will be measured in blood plasma samples of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Heart Failure</condition>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Non end-stage heart failure</arm_group_label>
    <description>Measurement of RNAs in non end-stage heart failure patients undergoing to left ventricle reconstruction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>End-stage heart failure</arm_group_label>
    <description>Measurement of RNAs in end-stage heart failure patients undergoing to left ventricular assisted device (LVAD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aortic Stenosis</arm_group_label>
    <description>Measurement of RNAs in patients affected by cardiac hypertrophy leading to aortic stenosis and requiring cardiac myectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Measurement of RNAs in individuals not affected by cardiovascular diseases</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>measurement of RNAs</intervention_name>
    <arm_group_label>Non end-stage heart failure</arm_group_label>
    <arm_group_label>End-stage heart failure</arm_group_label>
    <arm_group_label>Aortic Stenosis</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      cardiac tissue and blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cardiac surgery patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non end-stage heart failure

               -  left ventricle restoration surgery (SVR)

               -  End Systolic Volume Index (ESVI) &gt;35 ml/m2

               -  Ejection Fraction (EF)&lt;40%

               -  previous transmural anterior myocardial infarction (MI)

               -  age: 40-75

          2. End-stage heart failure

               -  left ventricle assisted device (LVAD) surgery

               -  age: 40-75

               -  Ejection Fraction (EF) &lt;25%

               -  End Systolic Volume Index (ESVI)≥60 ml/m2

          3. Aortic Stenosis

               -  aortic valve replacement

               -  intracardial pressure difference &gt;40 mmHg

               -  septal diameter ≥1.3 cm

        Exclusion Criteria:

          1. Non end-stage heart failure

               -  End Systolic Volume Index (ESVI)&lt;35 ml/m2

               -  Ejection Fraction (EF)&gt;40%

               -  Time from MI unknown

               -  Pregnancy

               -  Other genetic diseases

               -  Neoplasms

               -  Collagenopathies

               -  Chemo/radiotherapy

               -  Prolonged use of corticosteroids

               -  Infections

               -  Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and
                  Hepatitis C Virus (HCV) positive

          2. End-stage heart failure

               -  EF&gt;25%

               -  Time from MI unknown

               -  Pregnancy

               -  Other genetic diseases

               -  Neoplasms

               -  Collagenopathies

               -  Chemo/radiotherapy

               -  Prolonged use of corticosteroids

               -  Infections

               -  Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and
                  Hepatitis C Virus (HCV) positive

          3. Aortic Stenosis

               -  coronaropathies

               -  Pregnancy

               -  Other genetic diseases

               -  Neoplasms

               -  Collagenopathies

               -  Chemo/radiotherapy

               -  Prolonged use of corticosteroids

               -  Infections

               -  Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and
                  Hepatitis C Virus (HCV) positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Martelli, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS-POLICLINICO SAN DONATO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabio Martelli, Dr</last_name>
    <phone>+39 02 26437762</phone>
    <email>fabio.martelli@grupposandonato.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Irccs Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Milan</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FABIO MARTELLI, PhD</last_name>
      <phone>0252774683</phone>
      <email>fabio.martelli@grupposandonato.it</email>
    </contact>
    <investigator>
      <last_name>LORENZO MENICANTI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SIMONA GRECO, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SERENELLA CASTELVECCHIO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele De Bonis, MD, PhD</last_name>
      <email>debonis.michele@hsr.it</email>
    </contact>
    <investigator>
      <last_name>MICHELE DE BONIS, MD FESC FAHA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Donato</investigator_affiliation>
    <investigator_full_name>Fabio Martelli</investigator_full_name>
    <investigator_title>Dr, PhD, Molecular Cardiology Laboratory Director</investigator_title>
  </responsible_party>
  <keyword>miRNA</keyword>
  <keyword>lncRNAs</keyword>
  <keyword>transcriptome</keyword>
  <keyword>heart failure</keyword>
  <keyword>aortic stenosis</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

